natgillin/translations-raw huggingface dataset:
• Remove the syringe from the box and visually examine the syringe, as well as the medicine in the syringe. 
• Napolnjeno injekcijsko brizgo vzemite iz škatle in jo vizualno preglejte, preglejte tudi zdravilo skozi okence.
DAS28 ≤ 3.2, n (%) ACR20 response, n (%) ACR50 response, n (%) ACR70 response, n (%) 
DAS28 ≤ 3,2, n (%) odziv ACR20, n (%) odziv ACR50, n (%) odziv ACR70, n (%)
The syringe is closed by a rigid needle shield (elastomer seal with a polypropylene shell) and a plunger stopper (butyl rubber with a fluororesin coating). 
Injekcijska brizga je zaprta s trdnim varovalom za injekcijsko iglo (tesnilo iz elastomerja s polipropilenskim ovojem) in zamaškom bata (butilna guma, prevlečena s fluorirano smolo).
In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19 and CYP3A4 enzyme expression. 
Študije in vitro na kulturah človeških jetrnih celic so pokazale, da IL-6 zmanjša ekspresijo encimov CYP1A2, CYP2C9, CYP2C19 in CYP3A4.
Since RoActemra is given by a doctor or nurse, it is unlikely that you will miss a dose. 
Ker vam bo zdravilo RoActemra dal zdravnik ali medicinska sestra, ni verjetno, da bi izpustili odmerek.
All patients received background glucocorticoid (prednisone) therapy. 
Vsi bolniki so prejemali osnovno zdravljenje z glukokortikoidom (prednizon).
OTHER SPECIAL WARNING(S), IF NECESSARY Allow the syringe to sit at room temperature outside the box for 25 to 30 minutes before use 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Vzemite brizgo iz škatle in jo pustite na sobni temperaturi 25 do 30 minut pred uporabo
The bioavailability for the SC formulation was 0.8. 
Biološka uporabnost subkutane oblike je bila 0,8.
The rate of infections in the tocilizumab all exposure population was 163.7 per 100 patient years. 
Delež okužb v vsej populaciji, ki je prejemala tocilizumab, je bil 163,7 na 100 bolnik-let.
The safety of RoActemra has been studied in 5 Phase III, double-blind controlled trials and their extension periods. 
Varnost zdravila RoActemra so preučevali v petih dvojno slepih kontroliranih preskušanjih faze III ter v njihovih podaljšanih fazah.
Macrophage activation syndrome (MAS) is a serious life-threatening disorder that may develop in sJIA patients. 
Sindrom aktivacije makrofagov je resna, življenje ogrožajoča bolezen, ki se lahko razvije pri bolnikih s sJIA.
It is important to choose the correct angle to ensure the medication is delivered under the skin (into fatty tissue), otherwise the injection could be painful and the medication may not work. 
Pomembno je, da izberete pravilen kot, saj lahko le tako zagotovite prehod zdravila pod kožo (v maščobno tkivo), sicer je injekcija lahko boleča in morda zdravilo ne bi delovalo.
• It is important to use the correct angle to make sure the medicine is delivered under the skin (into fatty tissue), or the injection could be painful and the medicine may not work. 
• Pomembno je, da uporabite pravilen kot, da zagotovite injiciranje zdravila pod kožo (v maščobno tkivo), sicer je injiciranje lahko boleče in zdravilo morda ne bo delovalo.
• abdominal pain/tenderness and/or change in bowel function 
• bolečina v trebuhu/občutljivost in/ali spremembe v delovanju prebavil.
Study II, a two year study with planned analyses at week 24, week 52 and week 104, evaluated 1196 patients who had an inadequate clinical response to MTX. 
Študija II je bila dveletna študija z načrtovano analizo v 24., 52. ter 104. tednu, ocenila je 1196 bolnikov z nezadostnim kliničnim odzivom na metotreksat.
• simvastatin or atorvastatin, used to reduce cholesterol levels 
• simvastatin ali atorvastatin, ki se uporabljata za zniževanje koncentracije holesterola,
The safety profile comes from 4158 patients exposed to RoActemra in clinical trials; the majority of these patients were participating in RA studies (n=4009), while the remaining experience comes from GCA (n=149) studies. 
Podatki o varnostnih značilnosti izvirajo od 4158 bolnikov, izpostavljenih zdravilu RoActemra v kliničnih preskušanjih; večina teh bolnikov je sodelovala v študijah pri revmatoidnem artritisu (n = 4009), preostale izkušnje pa izvirajo iz študij pri GCA (n = 149).
• Do not leave the pre-filled pen to warm up in direct sunlight. 
• Napolnjenega injekcijskega peresnika med ogrevanjem ne izpostavljajte neposredni sončni svetlobi.
Health related and quality of life outcomes 
Izidi, povezani s splošnim zdravstvenim stanjem in kakovostjo življenja
These injection site reactions (including erythema, pruritus, pain and haematoma) were mild to moderate in severity. 
Reakcije na mestu injiciranja (vključno z eritemom, pruritusom, bolečino in hematomom) so bile blage do zmerne.
If an adult with RA or GCA or a child or adolescent with sJIA misses or forgets a dose 
Če odrasel z revmatoidnim artritisom ali GCA oziroma otrok ali mladostnik s sJIA izpusti ali pozabi odmerek
The majority was resolved without any treatment and none necessitated drug discontinuation. 
Večina je izzvenela brez zdravljenja in nobena ni zahtevala ukinitve zdravljenja.
Tocilizumab administered to cynomolgus monkeys during early gestation, was observed to have no direct or indirect harmful effect on pregnancy or embryonal-foetal development. 
Uporaba tocilizumaba pri opicah cynomolgus med zgodnjo gestacijo ni niti neposredno niti posredno škodljivo vplivala na nosečnost ali embrio-fetalni razvoj.
Prepare the Injection Site 
Pripravite mesto injiciranja
The efficacy of RoActemra for the treatment of CRS was assessed in a retrospective analysis of data from clinical trials of CAR T-cell therapies (tisagenlecleucel and axicabtagene ciloleucel) for hematological malignancies. 
Učinkovitost zdravila RoActemra pri zdravljenju CRS so ocenili v retrospektivni analizi podatkov iz kliničnih preskušanj zdravljenj s T-celicami s himernim antigenskim receptorjem (tisagenlecleucel in aksicabtagen ciloleucel) pri hematoloških malignostih.
• Place the pre-filled pen on a clean, flat surface and let the pre-filled pen warm up for 45 minutes to allow it to reach room temperature. 
• Napolnjeni injekcijski peresnik postavite na čisto, ravno površino in ga pustite 45 minut, da se ogreje na sobno temperaturo.
A higher frequency of injection site reactions was observed in the subcutaneous arms compared with placebo subcutaneous injections in the intravenous arms. 
Večjo pogostnost reakcij na mestu injiciranja so opazili v skupinah s subkutanim dajanjem v primerjavi s subkutanimi injekcijami placeba v skupinah z intravenskim dajanjem.
• abnormal liver function tests (increased transaminases) 
• nenormalni testi jetrnega delovanja (zvišanje transaminaz),
Japan 
Japonska
In this case you will get training on how to inject RoActemra yourself. 
V tem primeru vas bodo poučili, kako si lahko injicirate zdravilo RoActemra sami.
The study consisted of a 52-week blinded period (Part 1), followed by a 104-week open-label extension (Part 2). 
Študija je obsegala 52-tedensko slepo obdobje (1. del), ki mu je sledilo 104-tedensko podaljšanje z odprtim načrtom zdravljenja (2. del).
The comparator group was weekly MTX (dose titrated from 7.5 mg to a maximum of 20 mg weekly over an eight week period). 
Primerjalna skupina so bili bolniki, ki so tedensko dobivali metotreksat (odmerek so jim prilagajali od 7,5 mg do največ 20 mg na teden v obdobju osmih tednov).
The t1/2 of tocilizumab was concentration-dependent. 
Razpolovni čas (t1/2) tocilizumaba je odvisen od koncentracije.
No (N = 58) 
ne (n = 58)
If the plunger is not fully depressed the needle shield will not extend to cover the needle when it is removed. 
Če bat ni popolnoma potisnjen, se varovalo injekcijske igle ne bo podaljšalo, da bo iglo prekrilo, ko jo boste odstranili.
• Do not warm up the syringe in any other way. 
• Napolnjene injekcijske brizge ne segrevajte kakor koli drugače.
• RoActemra is used to treat adults and children aged 2 years and over with severe or lifethreatening cytokine release syndrome (CRS), a side-effect in patients treated with chimeric antigen receptor (CAR) T-cell therapies used to treat certain types of cancer. 
• Zdravilo RoActemra se uporablja za zdravljenje odraslih in otrok, starih 2 leti in več, s hudim ali življenje ogrožajočim sindromom sproščanja citokinov, neželenim učinkom pri bolnikih, zdravljenih s T-celicami s himernim antigenskim receptorjem (Chimeric Antigen Receptor, CAR) - terapije, ki se uporablja za zdravljenje določenih vrst raka.
No serious adverse reactions were observed in healthy volunteers who received a single dose up to 28 mg/kg, although dose limiting neutropenia was observed. 
Pri zdravih prostovoljcih, ki so dobili posamične odmerke do 28 mg/kg, ni bilo resnih neželenih učinkov, opazili pa so nevtropenijo, ki je omejila odmerek.
The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more. 
Običajni odmerek zdravila RoActemra je 8 mg na kg telesne mase, če tehtate 30 kg ali več.
The safety profile comes from 4510 patients exposed to RoActemra in clinical trials; the majority of these patients were participating in adult RA studies (n=4009), while the remaining experience comes from GCA (n=149), pJIA (n=240) and sJIA (n=112) studies. 
Povzetek varnostnih značilnosti Podatki o varnostnih značilnosti izvirajo od 4510 bolnikov, izpostavljenih zdravilu RoActemra v kliničnih preskušanjih; večina teh bolnikov je sodelovala v študijah pri revmatoidnem artritisu pri odraslih (n = 4009), preostale izkušnje pa izvirajo iz študij pri GCA (n = 149), pJIA (n = 240) in sJIA (n = 112).
Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of RoActemra. 
Blaga okvara ledvic (ocenjeni očistek kreatinina po Cockcroft-Gaultovi formuli) ni vplivala na farmakokinetiko zdravila RoActemra.
Patients who completed Part I of the study and achieved at least a JIA ACR30 response at week 16 compared to baseline were eligible to enter the blinded withdrawal period (Part II) of the study. 
Bolniki, ki so zaključili I. del študije in so po 16. tednih dosegli najmanj odziv JIA ACR 30 glede na izhodiščno vrednost, so se lahko vključili v slepo fazo odtegnitve (II.
• warfarin or phenprocoumon, used as a blood thinning agents 
• varfarin ali fenprokumon, ki se uporabljata za redčenje krvi,
The most commonly reported ADRs (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT. 
Najpogosteje opisani neželeni učinki (ki so se pojavili pri ≥ 5 % bolnikov, zdravljenih s tocilizumabom v monoterapiji ali v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili) so bili okužbe zgornjih dihal, nazofaringitis, glavobol, hipertenzija in zvišanje ALT.
RoActemra must not be given to children weighing less than 10 kg. 
Zdravila RoActemra ne smete dajati otrokom, ki tehtajo manj kot 10 kg.
• Recommendations for dose interruptions in sJIA and pJIA patients 
• priporočila za prekinitev odmerjanja pri bolnikih s sJIA in pJIA.
The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p<0.0001). 
Prilagojena povprečna sprememba v bolečini VAS po 12 tednih zdravljenja s tocilizumabom je bila zmanjšanje za 41 točk na skali 0-100 v primerjavi z zmanjšanjem za 1 za bolnike, ki so prejemali placebo (p < 0,0001).
• theophylline, used to treat asthma 
• teofilin, ki se uporablja za zdravljenje astme,
2 See section 4.4 
2 Glejte poglavje 4.4.
Talk to your doctor if you are pregnant, may be pregnant, or intend to become pregnant. 
Če ste noseči, če bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom.
They are usually effective, but can have side effects if used at high doses for a long time. 
Običajno so ta zdravila učinkovita, vendar pa lahko dolgotrajna uporaba velikih odmerkov vodi do pojava neželenih učinkov.
Do not attempt to use the upper arm area by yourself (See Figure D). 
Območja nadlahti ne uporabljajte, če si zdravilo dajete sami (glejte sliko D).
Week 24 ACR20, n (%) ACR50, n (%) 165 (56.9)** 139 (47.6) ACR70, n (%) 112 (38.6)** Week 52 ACR20, n (%) ACR50, n (%) 162 (55.9)** 144 (49.3) ACR70, n (%) 125 (43.1)** 105 (36.0) HAQ-DI (adjusted mean change from baseline) Week 52 
ACR, n (%) 142 (49,0)*** 115 (39,4) 24. teden ACR20, n (%) ACR50, n (%) 165 (56,9)** 139 (47,6) ACR70, n (%) 112 (38,6)** 88 (30,1) 52. teden ACR20, n (%) ACR50, n (%) 162 (55,9)** 144 (49,3) ACR70, n (%) 125 (43,1)** 105 (36,0)
Patients with latent TB should be treated with standard anti-mycobacterial therapy before initiating RoActemra. 
Bolniki z latentno tuberkulozo morajo pred uvedbo zdravila RoActemra dobiti standardno protimikrobno terapijo.
• Patient alert card - to address the risk of getting infections which can become serious if not treated. 
- da opozori na tveganje za okužbe, ki lahko postanejo resne, če niso zdravljene.
Exploratory Endpoints Week 24: ACR/EULAR Boolean Remission, n (%) ACR/EULAR Index Remission, n (%) Week 52: ACR/EULAR Boolean Remission, n (%) ACR/EULAR Index Remission, n (%) 
24. teden: ACR/EULAR remisija (Boolean), n (%) ACR/EULAR remisija (Index), n (%) 52. teden: ACR/EULAR remisija (Boolean), n (%) ACR/EULAR remisija (Index), n (%) mTSS - ocena po prirejeni Sharpovi lestvici (mTSS, modified Total Sharp Score)
> 3 x ULN to 5x ULN 
> 3- do 5-kratna ZMN
Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines. 
Tovrstne reakcije so lahko hujše in morebiti tudi smrtne pri bolnikih, pri katerih so se preobčutljivostne reakcije pojavile med predhodnim zdravljenjem z zdravilom RoActemra, tudi če so le-ti prejeli premedikacijo s steroidi in antihistaminiki.
• After you remove the green cap, the pre-filled pen is ready for use. 
• Ko odstranite zelen pokrovček, je napolnjeni injekcijski peresnik pripravljen za uporabo.
• Do not remove the needle-cap on your syringe until Step 5. 
• Ne odstranjujte pokrovčka za injekcijsko iglo na napolnjeni injekcijski brizgi do koraka 5.
• Continue to pinch the skin while you keep the pre-filled pen in place. 
• Še naprej držite kožno gubo, medtem ko držite napolnjeni injekcijski peresnik na mestu.
Hepatic transaminases increased, Weight increased, Total bilirubin increased* 
Preiskave zvišanje jetrnih transaminaz, zvečanje telesne mase, zvišanje celotnega bilirubina*
RoActemra is usually given in combination with another medicine for RA called methotrexate. 
Zdravilo RoActemra se po navadi uporablja v kombinaciji z drugim zdravilom za zdravljenje revmatoidnega artritisa, imenovanim metotreksat.
The primary endpoint was the proportion of patients achieving DAS28 remission (DAS28 < 2.6) at week 24. 
Primarni cilj je bil delež bolnikov, ki so dosegli remisijo glede na DAS28 (DAS28 < 2,6) v 24. tednu.
RoActemra subcutaneous formulation is not intended for intravenous administration. 
Subkutana oblika zdravila RoActemra ni namenjena intravenski aplikaciji.
Patients should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment. 
Bolnikom morate naročiti, naj se nemudoma posvetujejo z zdravnikom, če se pojavi kakršen koli simptom okužbe, da bodo deležni hitre ocene stanja in ustreznega zdravljenja.
If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C-8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če je bilo razredčenje opravljeno v nadzorovanih in validiranih aseptičnih pogojih.
The efficacy of tocilizumab was assessed in a three-part study WA19977 including an open-label extension in children with active pJIA. 
Učinkovitost tocilizumaba pri otrocih z aktivnim pJIA so ocenili v študiji WA19977, sestavljeni iz treh delov, vključno z odprtim, podaljšanim spremljanjem.
Do not use it if the expiration date has passed because it may not be safe to use. 
Če je rok uporabnosti potekel, ga ne uporabljajte, ker morda ni varen za uporabo.
• Do not inject into areas that could be bothered by a belt or waistband. 
• Ne injicirajte v mesta, kjer bi lahko prišlo do draženja s pasom.
The most common events occurring during infusion were headache, nausea and hypotension and within 24 hours of infusion were dizziness and hypotension. 
Najbolj pogosti neželeni učinki med infundiranjem so bili glavobol, navzea in hipotenzija, v 24 urah po infundiranju pa omotica in hipotenzija.
Most of the patients in the population pharmacokinetic analysis had normal renal function or mild renal impairment. 
Večina bolnikov v analizi populacijske farmakokinetike je imela normalno delovanje ledvic ali blago okvaro ledvic.
• Do not remove the pre-filled pen cap until you are ready to inject RoACTEMRA. 
• Ne odstranjujte pokrovčka napolnjenega injekcijskega peresnika, dokler niste pripravljeni na injiciranje zdravila RoACTEMRA.
In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12 mg/kg based upon body weight). 
V 12-tedenski, dvojno slepi, kontrolirani fazi je 75 bolnikov prejelo zdravljenje s tocilizumabom (8 mg/kg ali 12 mg/kg telesne mase).
• Do not use the syringe if it appears to be damaged 
• Ne uporabljajte napolnjene injekcijske brizge, če se vam zdi poškodovana.
For persistent increases in this range, reduce RoActemra dose frequency to every other week injection or interrupt RoActemra until alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have normalised. 
V primeru dolgotrajnih zvišanj v tem razponu zmanjšajte pogostnost odmerjanja injekcij zdravila RoActemra na enkrat na dva tedna ali prekinite njegovo uporabo, dokler se alanin-aminotransferaza (ALT) ali aspartat-aminotransferaza (AST) ne normalizira.
Ask your healthcare provider or pharmacist for information about where you can get a "sharps" container or what other types of puncture-resistant containers you can use to safely dispose of your used syringes, if you do not have one. 
Posvetujte se z zdravstvenim delavcem ali farmacevtom o tem, kje bi lahko dobili tak zabojnik oziroma kakšen zabojnik lahko uporabite za varno odstranitev uporabljenih napolnjenih injekcijskih brizg (glejte sliko I).
You will need the following to give your injection: Included in the box: 
Za dajanje injekcije boste potrebovali:
In the 12 week controlled phase, the rate of serious infections in the intravenous RoActemra group was 11.5 per 100 patient years. 
V 12-tedenski, kontrolirani fazi je bil delež resnih okužb v skupini, ki je prejemala intravensko obliko zdravila RoActemra, 11,5 na 100 bolnik-let.
Do not repeat the injection with another pre-filled pen. 
Injiciranja ne ponavljajte z drugim napolnjenim injekcijskim peresnikom.
All patients treated with RoActemra should be given the Patient Alert Card. 
Vsi bolniki, ki se zdravijo z zdravilom RoActemra, morajo dobiti opozorilno kartico za bolnika.
• The recommended injection sites are the front and middle of your thighs and the lower part of the abdomen below the navel (belly button) except for the five centimeter area directly around the navel. 
• Priporočena mesta injiciranja so sredinska sprednja stran stegen in spodnji del trebuha pod popkom, razen petcentimetrskega območja neposredno okoli popka (glejte sliko B).
A decrease in platelet count below 100 × 103 / μL was not observed in either of the placebo plus prednisone taper groups. 
Zmanjšanja števila trombocitov pod 100 × 103/µl niso opažali v nobeni od skupin, ki sta prejemali placebo in prednizon v zmanjšujočem se odmerku.
The steady-state profile following the RoActemra weekly dose was almost flat, with very little fluctuations between trough and peak values, while there were substantial fluctuations for the RoActemra every other weekly dose. 
Profil v stanju dinamičnega ravnovesja je bil po uporabi zdravila RoActemra vsak teden skoraj raven, z zelo majhnimi nihanji med najnižjimi in najvišjimi vrednostmi, medtem ko so bila nihanja pri uporabi zdravila RoActemra vsak drugi teden občutna.
Caution should be exercised when considering initiation of RoActemra treatment in patients with elevated ALT or AST > 1.5 x ULN. 
Previdnost je potrebna, če razmišljate o uvedbi zdravila RoActemra pri bolnikih, ki imajo ALT ali AST zvišano na > 1,5-kratno ZMN.
• To use the pre-filled pen, you first have to unlock the green Activation button. 
• Pred uporabo napolnjenega injekcijskega peresnika morate najprej odkleniti zelen gumb za aktivacijo.
Thirty patients (1.1%) developed neutralising antibodies. 
Pri 30 bolnikih (1,1 %) so se pojavila nevtralizacijska protitelesa.
The tocilizumab 8 mg/kg + MTX group also showed statistically significant results across the key secondary endpoints. 
V skupini s tocilizumabom 8 mg/kg in metotreksatom so bili statistično značilni tudi rezultati za ključne sekundarne cilje.
This leaflet was last revised 
Navodilo je bilo nazadnje revidirano Drugi viri informacij
Diarrhea pJIA, sJIA 
diareja pJIA, sJIA
• Do not touch the needle or let it touch any surface. 
• Ne prijemajte injekcijske igle in se z njo ne dotikajte nobenih površin.
• if you or a child patient you look after are allergic to tocilizumab or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični ali je bolnik otrok, za katerega skrbite, alergičen na tocilizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
The total patient exposure to RoActemra in the pJIA all exposure population was 184.4 patient years for IV and 50.4 patient years for SC tocilizumab. 
Skupna izpostavljenost bolnikov s pJIA zdravilu RoActemra je bila pri vsej izpostavljeni populaciji 184,4 bolnik-let za intravenski in 50,4 bolnik-let za subkutani tocilizumab.
Following SC dosing in sJIA patients, the absorption half-life was around 2 days, and the bioavailability for the SC formulation in sJIA patients was 95%. 
Po subkutanem odmerjanju pri bolnikih s sJIA je razpolovni čas absorpcije znašal približno 2 dneva; biološka uporabnost za subkutano obliko pri bolnikih s sJIA je bila 95 %.
RoActemra normalises expression of these enzymes. 
Zdravilo RoActemra normalizira ekspresijo teh encimov.
Four patients were tested positive for IgE isotype (0.9%). 
Pri štirih bolnikih se je pojavil izotip IgE (0,9 %).
In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion. 
V 12-tedenski, kontrolirani fazi je 16 % bolnikov v skupini, ki je prejemala tocilizumab in 5,4 % bolnikov v skupini, ki je prejemala placebo, doživelo neželeni učinek v 24 urah po infundiranju.
The dose should be calculated based on the patient's body weight at each administration. 
Odmerek je treba izračunati glede na bolnikovo telesno maso pred vsakim dajanjem.
Injection into muscle could result in an uncomfortable injection. 
Injiciranje v mišico lahko povzroči neugodje.
Caution should be exercised when considering initiation of RoActemra treatment in patients with a low platelet count (i.e. platelet count below 100 x 103/ μL). 
Previdnost je potrebna, če razmišljate o uvedbi zdravila RoActemra pri bolnikih z majhnim številom trombocitov (tj. številom trombocitov pod 100 x 103/µl).
• tiredness, 
• utrujenost,
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy. 
Glede na dolg eliminacijski razpolovni čas (t1/2) tocilizumaba lahko njegov učinek na aktivnost encima CYP450 traja še več tednov po koncu zdravljenja.
Your doctor will check for signs and symptoms of tuberculosis before starting RoActemra. 
Zdravnik vas bo preiskal glede znakov in simptomov tuberkuloze, preden vas bo začel zdraviti z zdravilom RoActemra.
Very rare side effects: These may affect up to 1 in every 10,000 patients 
Zelo redki neželeni učinki: Ti se lahko pojavijo pri največ 1 od 10.000 bolnikov.